Holen Sie sich die Stockscreener-App
1.3188
6.38%
-0.0912
Schlusskurs vom Vortag:
$1.41
Offen:
$1.41
24-Stunden-Volumen:
326.67K
Relative Volume:
0.38
Marktkapitalisierung:
$80.81M
Einnahmen:
$248.00K
Nettoeinkommen (Verlust:
$-149.34M
KGV:
-0.5416
EPS:
-2.4348
Netto-Cashflow:
$-128.71M
1W Leistung:
-0.75%
1M Leistung:
+18.92%
6M Leistung:
-16.98%
1J Leistung:
-13.16%
1-Tages-Spanne:
$1.315
$1.435
1-Wochen-Bereich:
$1.29
$1.435
52-Wochen-Spanne:
$1.09
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.315 | 86.64M | 248.00K | -149.34M | -128.71M | -2.4348 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.28 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.73 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
695.77 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.53 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.50 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Herabstufung | Needham | Buy → Hold |
| 2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-07 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-20 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Cowen | Outperform |
| 2020-06-29 | Eingeleitet | Needham | Buy |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
How Shareholder Activism Could Disrupt Pliant Therapeutics’ Strategy, Costs, and Stock Performance - TipRanks
Pliant Therapeutics (PLRX) Analyst Rating Update: Piper Sandler Lowers Price Target | PLRX Stock News - GuruFocus
Piper Sandler cuts Pliant Therapeutics stock price target to $3 By Investing.com - Investing.com Canada
Pliant Therapeutics Reports Q4 2025 Financial Results and Corporate Update – 8-K Filing Summary - Minichart
Pliant Therapeutics 2025 Annual Report: Business Overview, Risks, Regulatory Environment, and Competitive Landscape - Minichart
Pliant Therapeutics (PLRX) Advances Oncology Drug Development - GuruFocus
Pliant Therapeutics (NASDAQ:PLRX) Issues Quarterly Earnings Results - MarketBeat
PLRX: Net loss improved to $149.3M as focus shifted to PLN-101095; $192.4M cash on hand - TradingView
Oncology data and cost cuts reshape Pliant Therapeutics (NASDAQ: PLRX) - Stock Titan
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results - GlobeNewswire
Market Rankings: Is Pliant Therapeutics Inc stock good for income investorsQuarterly Profit Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Lyell Immunopharma, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Pliant Therapeutics Extends Stockholder Rights Agreement Expiration - TipRanks
PLRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pliant Therapeutics (PLRX) extends stockholder rights plan expiration to 2027 - Stock Titan
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference - Yahoo Finance
PLRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Pliant Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Momentum Shift: Is M I Homes Inc currently under institutional pressure2025 Technical Overview & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PLRX: Lead oncology program shows strong early efficacy and safety, with phase Ib starting in Q2 - TradingView
Analysts Are Neutral on These Healthcare Stocks: Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT) - The Globe and Mail
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration - Seeking Alpha
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference - The Manila Times
Pliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Investment Recap: What is the Moat Score of Pliant Therapeutics IncJuly 2025 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
PLRX Should I Buy - Intellectia AI
Should I hold or sell Pliant Therapeutics Inc. stock in 20252025 Winners & Losers & Short-Term Swing Trade Alerts - mfd.ru
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
Woodline Partners (PLRX) discloses 3.3% beneficial stake in Pliant - Stock Titan
PLRX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Chart Watch: What is Pliant Therapeutics Inc.’s book value per shareEarnings Growth Report & Weekly High Potential Stock Alerts - mfd.ru
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Short Interest Up 21.0% in January - MarketBeat
Idiopathic Pulmonary Fibrosis Market: Expanding Revenue - openPR.com
Aug Analyst Calls: Is GENC on track to beat earningsQuarterly Risk Review & High Conviction Buy Zone Alerts - baoquankhu1.vn
Portfolio Shifts: Is Pliant Therapeutics Inc. a potential multi baggerJuly 2025 Levels & Fast Gain Swing Trade Alerts - baoquankhu1.vn
Weekly Earnings: How cyclical is Pliant Therapeutics Incs revenue streamExit Point & Scalable Portfolio Growth Methods - baoquankhu1.vn
Breakout Zone: Why is Pliant Therapeutics Inc stock going upJuly 2025 Macro Moves & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of “Reduce” from Analysts - Defense World
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Rating of "Reduce" from Analysts - MarketBeat
Citadel Advisors LLC Acquires Additional Shares in Pliant Therapeutics Inc - GuruFocus
Quarterly Earnings: Is Pliant Therapeutics Inc a stock for growth or value investorsJuly 2025 Levels & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
What’s the beta of Pliant Therapeutics Inc. stockQuarterly Trade Report & Entry Point Confirmation Signals - mfd.ru
Pliant Therapeutics COO Kuo Minnie Sells $8853 in Shares By Investing.com - Investing.com UK
Pliant Therapeutics CHRO Cheung sells $9.6k in stock By Investing.com - Investing.com Nigeria
Bernard Coulie Sells 89,375 Shares of Pliant Therapeutics (NASDAQ:PLRX) Stock - MarketBeat
Pliant Therapeutics CHRO Cheung sells $9.6k in stock - Investing.com
Pliant therapeutics CFO Cummings sells $30,722 in stock By Investing.com - Investing.com Canada
Pliant therapeutics CEO Coulie sells $114k in shares By Investing.com - Investing.com Canada
Pliant therapeutics CEO Coulie sells $114k in shares - Investing.com
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pliant Therapeutics Inc-Aktie (PLRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Cheung Lily | Chief Human Resource Officer |
Jan 20 '26 |
Sale |
1.28 |
7,534 |
9,644 |
44,847 |
| Coulie Bernard | President and CEO |
Jan 20 '26 |
Sale |
1.28 |
89,375 |
114,400 |
505,601 |
| Kuo Minnie | Chief Operating Officer |
Jan 20 '26 |
Sale |
1.28 |
6,917 |
8,854 |
37,806 |
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):